GRASLND and papillary renal cell carcinoma: Thus far, GRASLND was reported as a prognostic factor in bladder cancer (Wang et al., 2020; Zhong et al., 2022), gastric cancer (Li et al., 2021), glioblastoma (Liu et al., 2021), head and neck squamous cell carcinoma (Hu et al., 2020), osteosarcoma (Rothzerg et al., 2021), and papillary renal cell carcinoma (Chen et al., 2021) by using bioinformatic pipelines and clinical data from the TCGA database.